SCHEMBL3534539

SCHEMBL3534539

CCCCCCCCN(C(C)(C)O)C(C)(C)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 3/20 0.46
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
TSHR P16473 2/20 0.40
THRB P10828 1/20 0.40
GBA1 P04062 1/20 0.39
GGPS1 O95749 5/20 0.38
LMNA P02545 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MGLL Q99685 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
FDPS P14324 4/20 0.37
AGTR1 P30556 1/20 0.37
OPRM1 P35372 1/20 0.37
PDE3A Q14432 1/20 0.37
S1PR2 O95136 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL438679 1.00 DNM1 (0.46) DNM1CA12CA1CA2CA9
SCHEMBL438629 1.00 DNM1 (0.46) DNM1CA12CA1CA2CA9
SCHEMBL4799222 1.00 DNM1 (0.46) DNM1CA12CA1CA2CA9
SCHEMBL439209 1.00 DNM1 (0.46) DNM1CA12CA1CA2CA9
SCHEMBL3538819 1.00 DNM1 (0.46) DNM1CA12CA1CA2CA9
SCHEMBL7760007 1.00 DNM1 (0.46) DNM1CA12CA1CA2CA9
SCHEMBL439341 1.00 DNM1 (0.46) DNM1CA12CA1CA2CA9
SCHEMBL10697643 0.97 DNM1 (0.42) DNM1CA12CA1CA2CA9
SCHEMBL440059 0.90 CA12 (0.36) DNM1CA12CA1CA2CA9
SCHEMBL437872 0.88 FAAH (0.45) LMNAHSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9133057-B2 Dialkanolamines as additives for grinding solids SIKA TECHNOLOGY AG (CH) 2015-09-15 US disclosed
EP-1812401-B1 METHOD FOR PRODUCING PERYLENE-3,4-DICARBOXYLIC ACID IMIDES BASF SE (DE) 2015-06-24 EP disclosed
US-20140150694-A1 DIALKANOLAMINES AS ADDITIVES FOR GRINDING SOLIDS SIKA TECHNOLOGY AG (CH) 2014-06-05 US disclosed
WO-2012160210-A1 DIALKANOLAMINES AS ADDITIVES FOR GRINDING SOLIDS SIKA TECHNOLOGY AG (CH) 2012-11-29 WO disclosed
US-7799920-B2 Method for producing perylene-3,4-dicarboxylic acid imides BASF AKTIENGESELLSCHAFT (DE) 2010-09-21 US disclosed
US-20080114170-A1 Method For Producing Perylene-3,4-Dicarboxylic Acid Imides BASF AKTIENGESELLSCHAFT (DE) 2008-05-15 US disclosed
EP-1812401-A1 METHOD FOR PRODUCING PERYLENE-3,4-DICARBOXYLIC ACID IMIDES BASF AKTIENGESELLSCHAFT (DE) 2007-08-01 EP disclosed
WO-2006050860-A1 METHOD FOR PRODUCING PERYLENE-3,4-DICARBOXYLIC ACID IMIDES BASF AKTIENGESELLSCHAFT (DE) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114170-A1 Method For Producing Perylene-3,4-Dicarboxylic Acid Imides CPNE4, IDH3A, RPL23A DNM1 658/4885CA12 324/4885CA1 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.